Orthofix Medical (NASDAQ:OFIX) Insider Jorge Andres Cedron Sells 3,743 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) insider Jorge Andres Cedron sold 3,743 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $12.82, for a total transaction of $47,985.26. Following the transaction, the insider owned 59,006 shares in the company, valued at $756,456.92. This represents a 5.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $12.65 on Tuesday. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $16.99. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.45 and a quick ratio of 1.43. The company’s 50-day moving average is $12.50 and its 200 day moving average is $14.08. The stock has a market capitalization of $507.77 million, a P/E ratio of -5.41 and a beta of 0.82.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Saturday, February 14th. The medical device company reported ($0.06) earnings per share for the quarter. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The firm had revenue of $219.91 million for the quarter. On average, sell-side analysts expect that Orthofix Medical Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Juniper Investment Company LLC grew its position in Orthofix Medical by 15.3% during the 3rd quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company’s stock valued at $41,681,000 after purchasing an additional 377,729 shares during the last quarter. Squarepoint Ops LLC grew its position in Orthofix Medical by 515.6% during the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company’s stock valued at $1,312,000 after purchasing an additional 98,552 shares during the last quarter. Tudor Investment Corp ET AL grew its position in Orthofix Medical by 268.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 217,044 shares of the medical device company’s stock valued at $3,178,000 after purchasing an additional 158,197 shares during the last quarter. JPMorgan Chase & Co. grew its position in Orthofix Medical by 33.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 258,035 shares of the medical device company’s stock valued at $3,778,000 after purchasing an additional 64,486 shares during the last quarter. Finally, Palumbo Wealth Management LLC purchased a new stake in Orthofix Medical during the 3rd quarter valued at about $629,000. Institutional investors own 89.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on OFIX shares. Wall Street Zen upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. TD Cowen assumed coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price target for the company. Barrington Research reissued an “outperform” rating and set a $17.00 price target on shares of Orthofix Medical in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus lowered their price target on shares of Orthofix Medical from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.25.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.